The management team and board of directors of Comodo Health comprise of pharmaceutical executives and pharmaceutical company owners with significant and meaningful hands-on operational experiences. Comodo Health employs a global view of drug development for greater efficiency while fully complying with current good manufacturing practices (cGMP) and FDA guidelines. The management team tremendously benefits from development, regulatory and commercial launch experiences in multiple specialty areas. Besides, we consider ourselves turn around specialists. We take great pride and joy from bringing products and businesses back to profits by stopping decline, and/or grow.

Management Team

Devrim Aran
President and CEO

Devrim Aran is the President and CEO of Comodo Health, Inc., where he is leading research and development, manufacture and commercialization of hospital injectables and drug/device combination products. Mr. Aran is responsible for managing Comodo Health’s business strategy and forward business direction.

Previously, Mr. Aran was Principal at Global Healthcare Enterprises and Senior Vice President at Adjility Health consulting for a wide variety of clients on global pharmaceuticals.

Prior to this, Mr. Aran was the Head of US Commercialization for one of the top oncology/hematology products at Novartis with more than $ 1 Billion in revenue. He was also a member of Novartis global development project team in Infectious Disease, Transplant and Immunology Business Unit.

Prior to Novartis, Mr. Aran was part of the executive leadership team at Abraxis Oncology that successfully developed and launched Abraxane, with major responsibilities for integration into American Pharmaceutical Partners.

Mr. Aran also held a number of successful and expanding roles at Roche Pharmaceuticals for Kytril, Pegasys, Amplicor and Roferon-A, where he started his pharmaceutical career in Acute Care Business Unit.

Mr. Aran has an MBA from Baruch College and an engineering degree from Istanbul Technical University.

Augustine Frimpong
Head of Global Regulatory Affairs and Compliance

Augustine Frimpong is the Head of Global Regulatory Affairs and Compliance. His responsibilities include providing both strategic and tactical solutions for the scientific, technical, regulatory and compliance; and project management aspects of Arkhe’s product development programs and product life cycle management

Mr. Frimpong is a proven Regulatory Affairs leader with more than 20 years of diverse industry experience in pharmaceutical and allied chemistry services. Most recently, Mr. Frimpong was Vice President of Regulatory Affairs and Compliance with Ascend Laboratories/ ThePharmaNetwork, LLC, where he led the regulatory affairs and cGMP compliance initiatives for the company’s pharmaceutical business.

His additional leadership roles have included Director of Regulatory Affairs/ Quality Assurance for TPN, Manager Regulatory Affairs for Actavis Totowa, Manager Regulatory Affairs/ Compliance for Perrigo Bronx (Clay Park Labs) and various Analytical Chemistry positions.

Augustine holds M.Sc degree from Memorial University of Newfoundland, St. John’s, Canada.

David Boyd
Clinical Advisor

David Boyd, PharmD is a 20-year industry veteran with experience across multiple therapeutic areas and development phases.

Dr. Boyd has been advising sponsors on programs for biologics, small molecules and generic products since 2012. Prior to that he was Director of Clinical Development at Osmotica Pharmaceuticals where he oversaw both generic and NDA projects including 505(b)2 and orphan drug development programs.

From 2003 to 2010 he was with Solvay Pharmaceuticals. His work there culminated with oversight of the Phase III program for CREON, the first FDA approved pancreatic enzyme supplement product indicated with the treatment of cystic fibrosis.

As a consultant from 2001 to 2003 he advised sponsors on Phase III development and Phase IV strategies for numerous biologic products including interleukin-antibody fusions proteins for solid tumor cancers.

Prior to that he was responsible for a large Phase IV program for Amgen’s consensus interferon that is indicated for the treatment of hepatitis C.